0DOL.L

Biofrontera AG [0DOL.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0DOL.L Stock Summary

In the News

0DOL.L Financial details

Company Rating
-
Market Cap
518.44K
Income
-10.57M
Revenue
28.45M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
91
Optionable
No
Shortable
Yes
Earnings
-
P/E
-6.25
Forward P/E
-
PEG
0.5
P/S
0.02
P/B
3.87
P/C
-
P/FCF
-
Quick Ratio
0.92
Current Ratio
1.67
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.17
EPS next Y
-
EPS next Q
-
EPS this Y
-213.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
30.95%
Revenue last 5Y
4.05%
Revenue Q/Q
106.67%
EPS Q/Q
-111.8%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-38%
ROE
-60%
ROC
0.08%
Gross Margin
80%
Oper. Margin
5%
Profit Margin
-37%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0-1.22
52W High
-
52W Low
-
RSI
59
Rel Volume
-
Avg Volume
276
Volume
Perf Week
1.93%
Perf Month
-
Perf Quarter
-
Perf Half Y
1.93%
-
-
-
-
Beta
0.657
-
-
Volatility
0.02%, 0.01%
Prev Close
0%
Price
1.17218
Change
-

Something similar

Top by Market Cap
MSFT
AVGO
APC.DE
1YD.DE
AAPL
Same Sector
EAR
TRSSF
MLSS
ORTX
ABC
Check Those
BBP
BFINVEST.NS
INDUSTOWER.NS
601995.SS
600476.SS
Similar Market Cap
OMTK
MJXL
SFE.L
DPCSW
OTIC

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 276
  • Market Capitalization 518.44K
  • Employee 91
  • CEO Ms. Pilar de la Huerta Martinez
  • Headquarters Leverkusen,DE
  • IPO Date 2023-04-21
  • Website https://www.biofrontera.com

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.